

January 7, 2002



1648
Bereskin & Parr

Anita Nador B.A. (Molec. Biophys./Biochem), LL.B.
416-957-1694 anador@bereskinparr.com
Bereskin & Parr Patent & Trademark Agents
Practice Restricted to Intellectual Property Law

Your Reference:

Our Reference: 9579-41

**INFORMATION DISCLOSURE
STATEMENT UNDER CFR.1.56 and CFR 1.97(b)**

The Commissioner of Patents
and Trademarks
Washington, D.C.
U.S.A 20231

Dear Sir:

Re: United States Patent Application Serial No.: 09/926,070
Title: Modulators of FGL2 Prothrombinase
Inventors: Gary Levy

RECEIVED
JAN 14 2002
TECH CENTER 1600/2900

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, the applicant hereby submits an Information Disclosure Statement including a listing of patents of which the applicant is aware. In accordance with the requirements of 1.97(b)(1) and (3), this Information Disclosure Statement is filed within three months of the filing date of the application or before the mailing date of a first Office Action on the merits, whichever event occurs last.


(A) List of References

A list of the patents and other publications of which the applicant is aware is set out in the attached PTO Form 1449 which is attached hereto.

(B) Copies of References

The applicant has attached hereto a copy of each of the references referred to in PTO Form 1449.

Respectfully submitted,
Gary Levy


Anita Nador
Registration No.:47,366

Bereskin & Parr
Box 401, 40 King Street West
Toronto, Ontario, Canada
M5H 3Y2
(416)364-7311

Encl.